Clinical efficacy of NUCALA
of patients had
ZERO flares vs
44% with placebo
Results are descriptive.
Primary endpoint results: Proportion of patients who experienced HES flare(s)* during the 32-week study or withdrew. NUCALA 28% vs placebo 56%, P=0.002.
the risk of flare*
Secondary endpoint results: 66% lower risk of first HES flare during the 32-week study or withdrew. NUCALA vs placebo (HR: 0.34; 95% CI: 0.18, 0.67, P=0.002).
CI=confidence interval, HR=hazard ratio.
Improvement in fatigue was based on Brief Fatigue Inventory (BFI) Item 3, which asked patients to record their worst level of weariness/tiredness severity during the past 24 hours. BFI scale: 0=no fatigue to 10=as bad as you can imagine.1,2 Baseline median BFI Item 3 scores: NUCALA: 4.46; Placebo: 4.69.3
Median change from baseline in BFI Item 3 at Week 32 in
“Worst level of fatigue in the past 24 hours”1
An MCID has not been established in the BFI for HES.
MCID=minimum clinically important difference.